SCHEMBL669913

SCHEMBL669913

Nc1nc(N)nc(-c2ccccc2F)n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.59
ADORA2A P29274 5/20 0.53
ADORA1 P30542 3/20 0.50
ADORA3 P0DMS8 2/20 0.50
ADORA2B P29275 2/20 0.50
POLB P06746 1/20 0.50
MPL P40238 1/20 0.48
ALOX15 P16050 2/20 0.48
KDM4E B2RXH2 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
NPC1 O15118 2/20 0.47
ALDH1A1 P00352 2/20 0.46
TSHR P16473 1/20 0.46
DCUN1D1 Q96GG9 1/20 0.44
HSP90AA1 P07900 2/20 0.43
DHPS P49366 1/20 0.43
BACE1 P56817 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29803060 1.00 SMN1; SMN2 (0.59) SMN1; SMN2ADORA2AADORA1ADORA3ADORA2B
SCHEMBL17046876 0.84 SMN1; SMN2 (0.71) SMN1; SMN2ADORA2AADORA1ADORA3ADORA2B
SCHEMBL30468191 0.84 SMN1; SMN2 (0.71) SMN1; SMN2ADORA2AADORA1ADORA3ADORA2B
SCHEMBL6307067 0.82 HSP90AA1 (0.69) SMN1; SMN2ADORA2AADORA1MPLALDH1A1
SCHEMBL10822469 0.78 SMN1; SMN2 (0.48) SMN1; SMN2ADORA2AADORA1ADORA3ADORA2B
SCHEMBL9566504 0.77 SMN1; SMN2 (0.63) SMN1; SMN2ADORA2AADORA1ADORA3ADORA2B
SCHEMBL16388461 0.77 CDK9 (0.47) SMN1; SMN2ADORA2AADORA1ADORA2BALOX15
SCHEMBL9566587 0.76 HRH4 (0.57) SMN1; SMN2ADORA2AADORA1ADORA3ADORA2B
SCHEMBL9566537 0.75 NPC1 (0.68) SMN1; SMN2ADORA2AADORA1ADORA3ADORA2B
SCHEMBL22468017 0.74 NPC1 (0.46) SMN1; SMN2ADORA2AKDM4ENPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118126325-A Low-temperature-cured alkali-soluble photosensitive resin and preparation method thereof 深圳先进电子材料国际创新研究院 2024-06-04 CN claimed
WO-2024046225-A1 ESTER TYPE PHOTOSENSITIVE POLYIMIDE COMPOSITE MATERIAL, PREPARATION METHOD AND SEMICONDUCTOR APPARATUS 深圳先进电子材料国际创新研究院 2024-03-07 WO claimed
CN-114805805-B Polyimide with high adhesive strength and preparation method and application thereof 深圳先进电子材料国际创新研究院 2023-12-19 CN claimed
CN-115509088-A Ester type photosensitive polyimide composite material, preparation method and semiconductor device 深圳先进电子材料国际创新研究院 2022-12-23 CN claimed
CN-114805805-A Polyimide with high bonding strength and preparation method and application thereof 中国科学院深圳先进技术研究院 2022-07-29 CN claimed
US-7081273-B2 Preparing coating solutions, coating on substrarte; applying vacuum; coagulating; removing solvent and additives from membrane in a series of leaching baths stirred with submersible ultrasonic cleaner;controlling and monitoring coating thickness ; collecting membrane; curing ACCORD PARTNER LIMITED (VG) 2006-07-25 US claimed
US-20060000766-A1 Method for producing defect free composite membranes ACCORD PARTNER LIMITED (VG) 2006-01-05 US claimed
CN-118126325-A Low-temperature-cured alkali-soluble photosensitive resin and preparation method thereof 深圳先进电子材料国际创新研究院 2024-06-04 CN disclosed
WO-2024046225-A1 ESTER TYPE PHOTOSENSITIVE POLYIMIDE COMPOSITE MATERIAL, PREPARATION METHOD AND SEMICONDUCTOR APPARATUS 深圳先进电子材料国际创新研究院 2024-03-07 WO disclosed
CN-114805805-B Polyimide with high adhesive strength and preparation method and application thereof 深圳先进电子材料国际创新研究院 2023-12-19 CN disclosed
US-11844802-B2 Compounds and compositions for ossification and methods related thereto EMORY UNIVERSITY (US) 2023-12-19 US disclosed
US-20230044670-A1 Compounds and Compositions for Ossification and Methods Related Thereto UNIV EMORY (US) 2023-02-09 US disclosed
CN-115509088-A Ester type photosensitive polyimide composite material, preparation method and semiconductor device 深圳先进电子材料国际创新研究院 2022-12-23 CN disclosed
US-9511071-B2 Compounds and compositions for ossification and methods related thereto EMORY UNIVERSITY (US) 2016-12-06 US disclosed
EP-2605804-A2 COMPOUNDS AND COMPOSITIONS FOR OSSIFICATION AND METHODS RELATED THERETO Emory University (US) 2013-06-26 EP disclosed
US-20130137634-A1 COMPOUNDS AND COMPOSITIONS FOR OSSIFICATION AND METHODS RELATED THERETO EMORY UNIVERSITY (US) 2013-05-30 US disclosed
US-8330039-B2 Solar cell modules with poly(vinyl butyral) encapsulant comprising unsaturated heterocyclic compound E I DU PONT DE NEMOURS AND COMPANY (US) 2012-12-11 US disclosed
WO-2012024489-A2 COMPOUNDS AND COMPOSITIONS FOR OSSIFICATION AND METHODS RELATED THERETO EMORY UNIVERSITY (US) 2012-02-23 WO disclosed
US-20100180947-A1 SOLAR CELL MODULES WITH POLY(VINYL BUTYRAL) ENCAPSULANT COMPRISING UNSATURATED HETEROCYCLIC COMPOUND E. I. DU PONT DE NEMOURS AND COMPANY (US) 2010-07-22 US disclosed
EP-0563386-A1 ANTICANCER COMPOSITION AND COMPOUND NIPPON SHINYAKU COMPANY, LIMITED (JP) 1993-10-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130137634-A1 COMPOUNDS AND COMPOSITIONS FOR OSSIFICATION AND METHODS RELATED THERETO BMP2, SOST, BMP4 SMN1; SMN2 2252/4885ADORA2A 181/4885ADORA1 432/4885
US-20230044670-A1 Compounds and Compositions for Ossification and Methods Related Thereto BMP2, SOST, BMP4 SMN1; SMN2 2252/4885ADORA2A 181/4885ADORA1 432/4885
US-11844802-B2 Compounds and compositions for ossification and methods related thereto BMP2, SOST, BMP4 SMN1; SMN2 2252/4885ADORA2A 181/4885ADORA1 432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.